Moxifloxacin
Brand: Avelox (US/EU) / Moxicip (IN) / Moxet (BD)
Antibiotic
Fluoroquinolone (respiratory)
Pharmacokinetics
| Half-life | 12 hours |
| Tmax | 1 h |
| Bioavailability | 90 % (approx) |
| Protein Binding | 50 % |
| Volume of Distribution | 2 L/kg (approx) |
| Clearance Route | hepatic |
| Active Metabolites | no |
| Notes | Do NOT use for UTI (poor urine concentrations); avoid in severe hepatic failure. |
⚠️ Safety & Warnings
Severity: Severe
Adverse Effects:
QT prolongation, tendonitis, CNS effects, dysglycemia
Contraindications:
QT prolongation history, severe hepatic disease
Precautions:
Avoid combining with QT drugs; not recommended for UTI treatment